ARCHER 1050: Study Design¹

First-line use of DACOPLICE^® was studied in a multicentre, multinational, randomised, open-label, Phase III, head-to-head trial with gefitinib.¹

Adapted from Wu YL, et al. 2017.

ARCHER 1050: Baseline characteristics (ITT population)¹

Adapted from Wu YL, et al. 2017.

Data are median (IQR) or n (%).¹

*EGFR mutation status was prospectively determined by local laboratory and commercially available tests (e.g. therascreen® EGFR RGQ PCR at accredited laboratories).^1
†Newly diagnosed with Stage IV at the time of study entry.^1
‡EGFR mutations (at randomisation) were identified from tumour specimens.^1
§At randomisation, 2 patients in the gefitinib group (and none in the DACOPLICE^® group) had the Thr790 Met mutation. At randomisation, 2 patients in the DACOPLICE^® group (and none in the gefitinib group) had the Thr790 Met mutation.

ARCHER, Adolescent Rural Cohort on Hormones, Education, Environment, Health and Relationships; CNS, central nervous system; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IQR, interquartile range; IRC, independent radiological central; ITT, intention-to-treat; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-free survival; PO, per orem (oral); PRO, patient-reported outcome; RECIST, Response Evaluation Criteria in Solid Tumours; RGQ, rotor-gene q; RMST, restricted mean survival time; TKI, tyrosine kinase inhibitor; TTF, time to treatment failure.

References: